Company Active LTD

Company profile

Ainostics Limited

UK company 11420367, incorporated on 18 June 2018.

AINOSTICS

AINOSTICS: ARTIFICIAL INTELLIGENCE ENABLED MEDICAL DIAGNOSTICS

Company number
11420367
Incorporated
18 Jun 2018
Companies House status
Active

Company identity

Founded / incorporated
18 June 2018

Company number 11420367

Verify at Companies House
Legal name
AINOSTICS LIMITED
Company type
LTD
Region
Unknown
Registered address
Unknown
Insolvency history
No

Latest accounts

Financial period: 1 Jul 2023 to 30 Jun 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
8

Company events

Reference milestones and recent Companies House filing stream events.

2 events
24 Sep
2026

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzU0NzQ2NTQxOGFkaXF6a2N4

Published 24 Sep 2026 20:05

18 Jun
2018

Incorporated

Inception

Company registered at Companies House

Public funding

12 awards
First funded
2019
Funded years
2019, 2020, 2021, 2022, 2023, 2024
Age at first award
0 years

Projects

2024 Collaborative R&D Lead participant

BR[AI]N...it's a no-brainer: First in Class Artificial Intelligence (AI) Enabled Digital Biomarker for Dementia Risk Prediction and Characterisation

1 May 2024 to 31 Jul 2026

Awarded
£1,194,552
Total cost £1,194,552

Despite the rapidly increasing numbers of people living with dementia, there are substantial difficulties with diagnosis. Around a third of people living with dementia have not received a diagnosis. Even in people who are diagnosed, there is typically a delay of years between developing symptoms and receiving a diagnosis. These problems mean that people a...

2023 Investment Accelerator Lead participant

Making Dementia a Forgotten Memory – Achieving FDA De Novo for the First Timely and Accurate Dementia Diagnostic Test

1 Dec 2023 to 30 Nov 2024

Awarded
£50,000
Total cost £50,000

Despite rapidly increasing numbers of people living with dementia, there are substantial problems with the timeliness and equity of dementia diagnosis. Around a third of sufferers have not received a diagnosis. People are referred to memory clinics when there is a suspicion that they might have dementia. However, there are other causes of memory difficult...

2023 Collaborative R&D Lead participant

CLAIR: first in class non-invasive test for outcome prediction and stratification in dementia

1 Jun 2023 to 31 May 2025

Awarded
£140,974
Total cost £201,391

Despite rapidly increasing numbers of people living with dementia, there are substantial difficulties with diagnosis. Around a third of people living with dementia have not received a diagnosis. Even in people who are diagnosed, there is typically a delay of years between developing symptoms and receiving a diagnosis. These problems mean that people are n...

2022 Collaborative R&D Lead participant

QUANTIMA: Non-invasive imaging driven patient identification, stratification and outcome prognosis in dementia

1 Apr 2022 to 30 Apr 2024

Awarded
£288,319
Total cost £411,884

Despite rapidly increasing numbers of people living with dementia, there are substantial difficulties with diagnosis. Around a third of people living with dementia have not received a diagnosis. Even in people who are diagnosed, there is typically a delay of years between developing symptoms and receiving a diagnosis. These problems mean that people are n...

2022 Collaborative R&D Lead participant

First in class non-invasive companion diagnostic test for dementia

1 Apr 2022 to 31 Mar 2024

Awarded
£169,596
Total cost £242,280

Despite rapidly increasing numbers of people living with dementia, there are substantial difficulties with diagnosis. Around a third of people living with dementia have not received a diagnosis. Even in people who are diagnosed, there is typically a delay of years between developing symptoms and receiving a diagnosis. These problems mean that people are n...

2022 Collaborative R&D Lead participant

Commercialisation of an imaging based dementia diagnostic test in the Chinese market - feasibility study

1 Jan 2022 to 31 Mar 2022

Awarded
£20,938
Total cost £29,912

Despite rapidly increasing numbers of people living with dementia, there are substantial difficulties with diagnosis. Around a third of people living with dementia have not received a diagnosis. Even in people who are diagnosed, there is typically a delay of years between developing symptoms and receiving a diagnosis. These problems mean that people are n...

2021 Collaborative R&D Lead participant

London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare - Resilience Funding Application

1 Dec 2021 to 31 Jan 2022

Awarded
£100,000
Total cost £100,000

Despite rapidly increasing numbers of people living with dementia, there are substantial difficulties with diagnosis. Around a third of people living with dementia have not received a diagnosis. Even in people who are diagnosed, there is typically a delay of years between developing symptoms and receiving a diagnosis. These problems mean that people are n...

2020 Study Lead participant

Data driven artificial intelligence engine for use in drug trials

1 Nov 2020 to 30 Apr 2022

Awarded
£277,780
Total cost £396,828

In healthcare, timely and personalised interventions have a crucial role in the ultimate effectiveness of both current and future treatments for a wide range of diseases. Rapid correct diagnosis is key in unlocking personalised approaches for degenerative diseases such as dementia and other neurodegenerative conditions, where stratification is mandatory f...

2020 Study Lead participant

Advanced non-invasive imaging biomarker for use in drug trials

1 Jun 2020 to 28 Feb 2022

Awarded
£324,233
Total cost £463,190

In healthcare, timely and personalised interventions have a crucial role in the ultimate effectiveness of both current and future treatments for a wide range of diseases. Rapid correct diagnosis is key in unlocking personalised approaches for degenerative diseases such as dementia and other neurodegenerative conditions, where stratification is mandatory f...

2020 Feasibility Studies Lead participant

Advanced non-invasive imaging biomarker for use in drug trials

1 Jun 2020 to 28 Feb 2021

Awarded
£116,070
Total cost £116,070

no public description

2020 Feasibility Studies Lead participant

Rapid triaging, treatment response assessment and outcome prediction in COVID-19 patients

1 Jun 2020 to 28 Feb 2021

Awarded
£74,455
Total cost £74,455

In healthcare, timely and personalised interventions have a crucial role in the ultimate effectiveness of both current and future treatments for a wide range of diseases. This is also true for COVID-19, where early detection would result in a significantly improved patient prognosis. AINOSTICS' technology represents a breakthrough that would provide an au...

2019 Feasibility Studies Lead participant

Anatomical Integrity Mapping (AIM): Non-invasive imaging driven patient identification, prognosis and stratification in dementia

1 Jul 2019 to 30 Jun 2021

Awarded
£319,156
Total cost £455,937

In healthcare, the timely and personalised interventions have a crucial role in the ultimate effectiveness of both current and future treatments for a wide range of diseases. Rapid correct diagnosis is key in unlocking personalised approaches for degenerative diseases like dementia and fibrosis where stratification is mandatory for correct treatment. Earl...

Product types

Collaborative R&D Feasibility Studies Investment Accelerator Study